Gayle A. Crowell, a member of the board of Hercules Capital, Inc. (NASDAQ: HTGC), purchased 7,317 shares of the companys common stock on March 26, 2026, according to a Form 4 filing with the Securities and Exchange Commission.
The total value of the acquisition was $104,998. The filing lists an average purchase price of $14.35 per share, with individual share prices in the transaction ranging from $14.31 to $14.39. After the transaction, Crowell is reported to directly own 97,589 shares of Hercules Capital.
The purchase resulted from Crowells election to receive stock instead of cash as compensation for her services as a director. The reported tally of shares includes shares acquired under Hercules Capitals dividend reinvestment plan, which the filing indicates is exempt under Rule 16a-11.
Market context noted in the filing and associated disclosures points to the shares trading near a 52-week low of $13.70. At the time of the referenced market check, shares were trading at $14.17 and had declined nearly 24% year-to-date.
Hercules Capital continues to offer a high dividend yield to shareholders, cited at 13.53% in the materials accompanying the filing. The company has maintained dividend payments for 22 consecutive years, according to the same disclosures.
In related corporate developments, Hercules Capital provided preliminary fourth-quarter estimates, projecting net asset value per share between $12.10 and $12.16 as of December 31, 2025, up from a reported NAV per share of $12.05 at the end of September 2025.
The firm also amended a loan agreement with Savara Inc., making available up to an additional $75 million in funding that is contingent on U.S. Food and Drug Administration approval of Savaras investigational therapy, MOLBREEVI. Savaras broader financing structure noted in the disclosures includes a separate $75 million royalty financing agreement with RTW.
Hercules Capital has faced external scrutiny stemming from a short report by Hunterbrook that questioned the firms valuation of software-related debt and the sustainability of its dividend. The companys portfolio includes approximately 35% exposure to software debt, a concentration highlighted as a potential source of stress. In the wake of these concerns, Piper Sandler downgraded Hercules Capital from Overweight to Neutral, citing risks tied to disruption in the software sector.
The details in the Form 4 and the companys regulatory disclosures provide a snapshot of director-level buying alongside ongoing operational and market pressures. The purchase via a compensation election and the use of the dividend reinvestment plan are executed within existing corporate governance and reporting frameworks.